%0 Journal Article
%T Immune response regulation by transduced mesenchymal stem cells with decorin gene on bleomycin-induced lung injury, fibrosis, and inflammation.
%A Xu W
%A Li CK
%A Yang LS
%A Nasab EM
%A Athari SS
%A Gu WD
%J Allergol Immunopathol (Madr)
%V 52
%N 4
%D 2024
%M 38970265
%F 2.094
%R 10.15586/aei.v52i4.1104
%X <B>BACKGROUND: </B>Pulmonary fibrosis is a pathological hallmark of lung injury. It is an aggressive disease that replaces normal lung parenchyma by fibrotic tissue. The transforming growth factor-beta-mothers against decapentaplegic homolog 3 (TGF-β1-Smad3) signaling pathway plays a key role in regulating lung fibrosis. Decorin (DCN), a small leucine-rich proteoglycan, has a modulatory effect on the immune system by reversibly binding with TGF-β and reducing its bioavailability. Mesenchymal stem cell (MSC) therapy is a new strategy that has an immune-modulatory capacity.<BR><B>OBJECTIVE: </B>The aim of this study was to introduce a new therapeutic approach to harness remodeling in injured lung.<BR><B>METHODS: </B>Bone marrow MSCs were isolated and transduced by decorin gene. Lung injury was induced by bleomycin and mice were treated with MSCs, MSCs-decorin, and decorin. Then, oxidative stress biomarkers, remodeling biomarkers, bronchoalveolar lavage cells, and histopathology study were conducted.<BR><B>RESULTS: </B>Reduced catalase and superoxide dismutase increased due to treatments. Elevated malondialdehyde, hydroxyproline, TGF-β levels, and polymorphonuclear cells count decreased in the treated groups. Additionally, the histopathology of lung tissues showed controlled inflammation and fibrosis.<BR><B>CONCLUSIONS: </B>Transfected decorin gene to MSCs and used cell therapy could control remodeling and bleomycin-induced lung injury.